Shopping Cart 0
Cart Subtotal
USD 0

Abcam Plc (ABC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondary antibodies, immunoassay kits and reagents, cell and tissue imaging tools, cellular and biochemical assays, proteins and peptides, proteomics tools, agonists, activators, antagonists and inhibitors, lysates, and multiplex miRNA assay. Abcam's products are used by life science researchers to identify proteins for life sciences and veterinary sciences. The company distributes its products in the Americas, Europe, Asia-Pacific and other countries. Abcam is headquartered in Cambridge, Cambridgeshire, the UK.

Abcam Plc (ABC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Abcam Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Abcam Plc, Medical Devices Deals, 2012 to YTD 2018 10

Abcam Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Abcam Plc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

AxioMx Raises USD 2 Million In Second Round Of Venture Financing 12

AxioMx Raises USD 2 Million In Venture Financing 13

AxioMx Raises Additional USD 0.5 Million In Venture Financing 14

Partnerships 15

Abcam Enters into Agreement with Institute Of Molecular And Cell Biology 15

Licensing Agreements 16

Abcam Enters into Licensing Agreement with Roche 16

Abcam Enters into Licensing Agreement with Horizon Discovery 17

Children's Cancer Institute Enters into Licensing Agreement with Abcam 18

TGR BioSciences Enters Into Licensing Agreement With Abcam 19

Abcam Enters Into Licensing Agreement With Pfizer 20

Equity Offering 21

Abcam Completes Private Placement Of Shares For USD 77 Million 21

Acquisition 22

Abcam Acquires AxioMx 22

Abcam Acquires Firefly BioWorks for USD28 Million in Tender Offer 23

Abcam Completes Acquisition Of Epitomics, Rabbit Monoclonal Antibodies Provider, For USD 155 Million 24

Abcam Plc-Key Competitors 25

Abcam Plc-Key Employees 26

Abcam Plc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 29

Financial Announcements 29

Sep 10, 2018: Abcam: Preliminary results 2018 29

Mar 05, 2018: Abcam: Interim results for the six months ended 31 December 2017 31

Sep 11, 2017: Abcam: Double-digit earnings growth enabling investment for sustained future growth 32

Corporate Communications 33

Oct 30, 2018: Abcam appoints Cheri Walker, PhD, as Senior Vice President, Corporate Development 33

Jun 18, 2018: Abcam Appoints Peter Allen As Chairman 34

Nov 15, 2017: ABCAM: Result of AGM and Directorate Change 35

Oct 11, 2017: Abcam: Directorate Change-Chairman 36

Product News 37

Feb 06, 2018: Introducing FirePlex-HT High-throughput Multiplex Immunoassays-Delivering More Data from Precious Samples 37

Other Significant Developments 38

Jul 27, 2017: Abcam: Pre-Close Period Update 38

Mar 06, 2017: Abcam: Interim Results delivering double digit sales growth 39

Appendix 40

Methodology 40

About GlobalData 40

Contact Us 40

Disclaimer 40


List Of Figure

List of Figures

Abcam Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Abcam Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Abcam Plc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Abcam Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Abcam Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Abcam Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Abcam Plc, Medical Devices Deals, 2012 to YTD 2018 10

Abcam Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AxioMx Raises USD 2 Million In Second Round Of Venture Financing 12

AxioMx Raises USD 2 Million In Venture Financing 13

AxioMx Raises Additional USD 0.5 Million In Venture Financing 14

Abcam Enters into Agreement with Institute Of Molecular And Cell Biology 15

Abcam Enters into Licensing Agreement with Roche 16

Abcam Enters into Licensing Agreement with Horizon Discovery 17

Children's Cancer Institute Enters into Licensing Agreement with Abcam 18

TGR BioSciences Enters Into Licensing Agreement With Abcam 19

Abcam Enters Into Licensing Agreement With Pfizer 20

Abcam Completes Private Placement Of Shares For USD 77 Million 21

Abcam Acquires AxioMx 22

Abcam Acquires Firefly BioWorks for USD28 Million in Tender Offer 23

Abcam Completes Acquisition Of Epitomics, Rabbit Monoclonal Antibodies Provider, For USD 155 Million 24

Abcam Plc, Key Competitors 25

Abcam Plc, Key Employees 26

Abcam Plc, Subsidiaries 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Abcam Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondary antibodies, immunoassay kits and reagents, cell and tissue imaging tools, cellular and biochemical assays, proteins and peptides, proteomics tools, agonists, activators, antagonists and inhibitors, lysates, and multiplex miRNA assay. Abcam's products are used by life science researchers to identify proteins for life sciences and veterinary sciences. The company distributes its products in the Americas, Europe, Asia-Pacific and other countries. Abcam is headquartered in Cambridge, Cambridgeshire, the UK.

Abcam Plc (ABC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Abcam Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Abcam Plc, Medical Devices Deals, 2012 to YTD 2018 10

Abcam Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Abcam Plc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

AxioMx Raises USD 2 Million In Second Round Of Venture Financing 12

AxioMx Raises USD 2 Million In Venture Financing 13

AxioMx Raises Additional USD 0.5 Million In Venture Financing 14

Partnerships 15

Abcam Enters into Agreement with Institute Of Molecular And Cell Biology 15

Licensing Agreements 16

Abcam Enters into Licensing Agreement with Roche 16

Abcam Enters into Licensing Agreement with Horizon Discovery 17

Children's Cancer Institute Enters into Licensing Agreement with Abcam 18

TGR BioSciences Enters Into Licensing Agreement With Abcam 19

Abcam Enters Into Licensing Agreement With Pfizer 20

Equity Offering 21

Abcam Completes Private Placement Of Shares For USD 77 Million 21

Acquisition 22

Abcam Acquires AxioMx 22

Abcam Acquires Firefly BioWorks for USD28 Million in Tender Offer 23

Abcam Completes Acquisition Of Epitomics, Rabbit Monoclonal Antibodies Provider, For USD 155 Million 24

Abcam Plc-Key Competitors 25

Abcam Plc-Key Employees 26

Abcam Plc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 29

Financial Announcements 29

Sep 10, 2018: Abcam: Preliminary results 2018 29

Mar 05, 2018: Abcam: Interim results for the six months ended 31 December 2017 31

Sep 11, 2017: Abcam: Double-digit earnings growth enabling investment for sustained future growth 32

Corporate Communications 33

Oct 30, 2018: Abcam appoints Cheri Walker, PhD, as Senior Vice President, Corporate Development 33

Jun 18, 2018: Abcam Appoints Peter Allen As Chairman 34

Nov 15, 2017: ABCAM: Result of AGM and Directorate Change 35

Oct 11, 2017: Abcam: Directorate Change-Chairman 36

Product News 37

Feb 06, 2018: Introducing FirePlex-HT High-throughput Multiplex Immunoassays-Delivering More Data from Precious Samples 37

Other Significant Developments 38

Jul 27, 2017: Abcam: Pre-Close Period Update 38

Mar 06, 2017: Abcam: Interim Results delivering double digit sales growth 39

Appendix 40

Methodology 40

About GlobalData 40

Contact Us 40

Disclaimer 40


List Of Figure

List of Figures

Abcam Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Abcam Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Abcam Plc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Abcam Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Abcam Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Abcam Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Abcam Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Abcam Plc, Medical Devices Deals, 2012 to YTD 2018 10

Abcam Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AxioMx Raises USD 2 Million In Second Round Of Venture Financing 12

AxioMx Raises USD 2 Million In Venture Financing 13

AxioMx Raises Additional USD 0.5 Million In Venture Financing 14

Abcam Enters into Agreement with Institute Of Molecular And Cell Biology 15

Abcam Enters into Licensing Agreement with Roche 16

Abcam Enters into Licensing Agreement with Horizon Discovery 17

Children's Cancer Institute Enters into Licensing Agreement with Abcam 18

TGR BioSciences Enters Into Licensing Agreement With Abcam 19

Abcam Enters Into Licensing Agreement With Pfizer 20

Abcam Completes Private Placement Of Shares For USD 77 Million 21

Abcam Acquires AxioMx 22

Abcam Acquires Firefly BioWorks for USD28 Million in Tender Offer 23

Abcam Completes Acquisition Of Epitomics, Rabbit Monoclonal Antibodies Provider, For USD 155 Million 24

Abcam Plc, Key Competitors 25

Abcam Plc, Key Employees 26

Abcam Plc, Subsidiaries 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Abcam Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.